SX 011

Cat. No.: HY-108646

CAS No.: 309913-42-6

Molecular Formula: $C_{26}H_{27}ClFN_3O_3$

Molecular Weight: 483.96

Target: p38 MAPK; JNK

Pathway: MAPK/ERK Pathway

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SX 011 is a p38 inhibitor with IC_{50}s of 9 nM and 90 nM against p38α and p38β, respectively. SX 011 also inhibits JNK-2 with an IC_{50} of 100 nM. SX-011 is orally bioavailable[1].			
IC_{50} & Target	p38α 9 nM (IC_{50})	p38β 90 nM (IC_{50})	p38δ > 300,000 nM (IC_{50})	p38γ > 300,000 nM (IC_{50})
	JNK2 100 nM (IC_{50})	JNK1 > 300,000 nM (IC_{50})		
In Vitro	SX-011 inhibits LPS stimulated TNFα and interleukin-1β (IL-1β) from human peripheral blood mononuclear cells (PBMC) with an IC_{50} of 200 nM and 900 nM, respectively. Additionally, IL-6 (IC_{50} 250 nM) and IL-8 (IC_{50} 100 nM) are significantly inhibited in this assay[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	SX-011 is orally bioavailable in preclinical species (rat, 24%; monkey, 29%; dog, 43%) and has demonstrated efficacy in both acute and chronic models of inflammation in rats. Rat $t_{1/2}$ = 30 min[1][2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

REFERENCES

[1]. Lee MR, et al. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem. 2005;12(25):2979-94.

[2]. Hynes J Jr, et al. Small molecule p38 inhibitors: novel structural features and advances from 2002-2005. Curr Top Med Chem. 2005;5(10):967-85.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA